Background Pregnant women with type 1 diabetes are a high-risk population who are
recommended to strive for optimal glucose control, but neonatal outcomes attributed to
maternal hyperglycaemia remain suboptimal. Our aim was to examine the effectiveness of
continuous glucose monitoring (CGM) on maternal glucose control and obstetric and
neonatal health outcomes. Methods In this multicentre, open-label, randomised controlled
trial, we recruited women aged 18–40 years with type 1 diabetes for a minimum of 12 …

The use of continuous glucose monitoring (CGM) has been increasing, especially in patients
with type 1 diabetes, partly due to improved accuracy with lower mean amplitude relative
difference (about 10%) with the newer or implantable sensors. 1, 2 Most real-time
subcutaneous sensors are approved for 7 days—except for the implantable sensor, which
lasts 3 months—and require two calibrations per day. 1–3 One on-demand sensor is
approved for 14 days and needs no calibrations. 2 Improved health outcomes, such as …